ENTLEP001 / Entos Pharma - LARVOL DELTA

Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) for its Congenital Generalized Lipodystrophy Program (Businesswire) - "Entos Pharmaceuticals...announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M USD grant. The funds will support the completion of IND-enabling activities for the development of ENTLEP001, a durable genetic medicine for the treatment of congenital generalized lipodystrophy (CGL)."

Financing • Lipodystrophy